date/time interval
- July 1, 2022 - June 30, 2023
Zanubrutinib and Venetoclax as Initial Therapy for CLL with Obinutuzumab Consolidation in Patients with Minimal Residual Disease Positivity.
Grant
Overview
awarded by
administered by
sponsor award ID
- ASCO 221054-01
Affiliation
contributor
- Allan, John Principal Investigator 2022 - 2023